Search research articles
Contact Us
Filters
Showing results (31-40 of 40) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 40 results.
Clinical Journal of the American Society of Nephrology : CJASN
|
June 25, 2016
Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis
Geoffrey A Block, David P Rosenbaum, Maria Leonsson-Zachrisson, et al.
Digestive Diseases (Basel, Switzerland)
|
December 19, 2024
Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete Spontaneous Bowel Movement Frequency in Adults with Irritable Bowel Syndrome with Constipation
Darren M Brenner, Gregory S Sayuk, Brooks D Cash, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology
|
January 22, 2024
NHE3 inhibitor tenapanor maintains intestinal barrier function, decreases visceral hypersensitivity, and attenuates TRPV1 signaling in colonic sensory neurons
Andrew J King, Lin Chang, Qian Li, et al.
The American Journal of Gastroenterology
|
January 31, 2024
Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis
Anthony J Lembo, William D Chey, Lucinda A Harris, et al.
The American Journal of Gastroenterology
|
May 4, 2026
Correction to: Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis
Anthony J Lembo, William D Chey, Lucinda A Harris, et al.
Science Translational Medicine
|
March 14, 2014
Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans
Andrew G Spencer, Eric D Labonte, David P Rosenbaum, et al.
Kidney360
|
February 7, 2024
Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study
Stuart M Sprague, Daniel E Weiner, David P Tietjen, et al.
Kidney360
|
April 17, 2026
Correction to: Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study
Stuart M Sprague, Daniel E Weiner, David P Tietjen, et al.
Science Translational Medicine
|
August 31, 2018
Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability
Andrew J King, Matthew Siegel, Ying He, et al.
Annals of Neurology
|
November 7, 2024
Association of Reperfusion and Procedural Characteristics with Endovascular Thrombectomy Outcomes in Large Core Stroke: Sub-Analysis from the SELECT2 Trial
Ameer E Hassan, Michael G Abraham, Spiros Blackburn, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 40) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 40 results.
Clinical Journal of the American Society of Nephrology : CJASN
|
June 25, 2016
Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis
Geoffrey A Block, David P Rosenbaum, Maria Leonsson-Zachrisson, et al.
Digestive Diseases (Basel, Switzerland)
|
December 19, 2024
Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete Spontaneous Bowel Movement Frequency in Adults with Irritable Bowel Syndrome with Constipation
Darren M Brenner, Gregory S Sayuk, Brooks D Cash, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology
|
January 22, 2024
NHE3 inhibitor tenapanor maintains intestinal barrier function, decreases visceral hypersensitivity, and attenuates TRPV1 signaling in colonic sensory neurons
Andrew J King, Lin Chang, Qian Li, et al.
The American Journal of Gastroenterology
|
January 31, 2024
Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis
Anthony J Lembo, William D Chey, Lucinda A Harris, et al.
The American Journal of Gastroenterology
|
May 4, 2026
Correction to: Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis
Anthony J Lembo, William D Chey, Lucinda A Harris, et al.
Science Translational Medicine
|
March 14, 2014
Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans
Andrew G Spencer, Eric D Labonte, David P Rosenbaum, et al.
Kidney360
|
February 7, 2024
Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study
Stuart M Sprague, Daniel E Weiner, David P Tietjen, et al.
Kidney360
|
April 17, 2026
Correction to: Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study
Stuart M Sprague, Daniel E Weiner, David P Tietjen, et al.
Science Translational Medicine
|
August 31, 2018
Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability
Andrew J King, Matthew Siegel, Ying He, et al.
Annals of Neurology
|
November 7, 2024
Association of Reperfusion and Procedural Characteristics with Endovascular Thrombectomy Outcomes in Large Core Stroke: Sub-Analysis from the SELECT2 Trial
Ameer E Hassan, Michael G Abraham, Spiros Blackburn, et al.
Page
of 4